| Bioactivity | CD12681 (compound 14) is a potent and selective RORγ inverse agonist with IC50 of 19 nM and 10 nM for RORγ GAL4 and CD4-IL-17 cells, respectively. CD12681 decreases the IL-17 inflammatory cell recruitment. CD12681 has the potential for the research of psoriasis[1]. |
| Invitro | CD12681 (compound 14) shows inhibition with IC50s of 44, >25, 9 µM for CYP 3A4, CYP 2D6, hERG, respectively[1]. |
| Name | CD12681 |
| CAS | 1952239-59-6 |
| Formula | C25H33N3O4S |
| Molar Mass | 471.61 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ouvry G, et al. Discovery and Characterization of CD12681, a Potent RORγ Inverse Agonist, Preclinical Candidate for the Topical Treatment of Psoriasis. ChemMedChem. 2018 Feb 20;13(4):321-337. |